SURMOUNT -5 clinical trial data,Tirzepatide vs Semaglutide in obesity

Tirzepatide is the first and only approved GIP and GLP-1 receptor agonist³

Tirzepatide demonstrated superior reduction in body weight compared to Semaglutide¹

• ^aData are least-squares mean with 95% confidence intervals or no. (%). Only the Week 72 timepoint was pre-specified and controlled for multiplicity.¹
• Efficacy estimand, mITT population, MMRM analysis.¹
• Participants in both the Tirzepatide and Semaglutide treatment arms received lifestyle intervention, including a reduced-calorie diet and increased physical activity.¹
• Studied in a randomized, open-label, phase 3b trial of adults with obesity (BMI ≥30 kg/m²), or overweight (BMI ≥27 kg/m²) with at least 1 obesity-related complication (e.g., hypertension, dyslipidemia), excluding diabetes. The study included a 2-week screening period and a 72-week treatment period.¹
• Limitations of an open-label study may be related to a bias in evaluation of the outcomes, efficacy and/or safety, and analysis was not tested against a placebo-controlled comparison group.
• Efficacy estimand results are supported by the reference, including supplemental information.

What could tirzepatide mean for your patients with obesity or overweight with at least 1 obesity-related complication?¹

In SURMOUNT-5, participants on tirzepatide MTD (10 mg or 15 mg) achieved superior reduction in body weight

• Studied in a randomized, open-label, phase 3b trial of adults with obesity (BMI ≥30 kg/m²), or overweight (BMI ≥27 kg/m²) with at least 1 obesity-related complication (eg, hypertension, dyslipidemia), excluding diabetes. The study included a 2-week screening period and a 72-week treatment period.¹
• Participants in both the tirzepatide and semaglutide treatment arms received lifestyle intervention, including a reduced-calorie diet and increased physical activity.¹
• Limitations of an open-label study may be related to a bias in the evaluation of the outcomes, efficacy, and/or safety, and analysis was not tested against a placebo-controlled comparison group.
• ⁺Tirzepatide MTD was either 10 mg or 15 mg. Semaglutide MTD was either 1.7 mg or 2.4 mg. Efficacy estimand, mITT population, MMRM analysis.¹
• Efficacy estimand results are supported by the reference, including supplemental information. Data are least-squares mean.¹

Key secondary endpoint: Percentage of participants who achieved weight reduction targets at 72 weeks¹

• Studied in a randomized, open-label, phase 3b trial of adults with obesity (BMI ≥30 kg/m²), or overweight (BMI ≥27 kg/m²) with at least 1 obesity-related complication (eg, hypertension, dyslipidemia), excluding diabetes. The study included a 2-week screening period and a 72-week treatment period.¹
• Participants in both the tirzepatide and semaglutide treatment arms received lifestyle intervention, including a reduced-calorie diet and increased physical activity.¹
• Efficacy estimand, mITT population. MMRM analysis.¹
• Limitations of an open-label study may be related to a bias in the evaluation of the outcomes, efficacy and/or safety, and analysis was not tested against a placebo-controlled comparison group.
• Efficacy estimand results are supported by the reference, including supplemental information. ^$Data are least-squares mean with 95% CIs or no. (%).¹

What could tirzepatide mean for your patients with obesity or overweight with at least 1 obesity-related complication?¹

In SURMOUNT-5, a higher percentage of participants on tirzepatide MTD (10 mg or 15 mg) achieved weight reduction targets, including ≥ 25% weight reduction

• Studied in a randomized, open-label, phase 3b trial of adults with obesity (BMI ≥30 kg/m²), or overweight (BMI ≥27 kg/m²) with at least 1 obesity-related complication (eg, hypertension, dyslipidemia), excluding diabetes. The study included a 2-week screening period and a 72-week treatment period.¹
• Participants in both the tirzepatide and semaglutide treatment arms received lifestyle intervention, including a reduced-calorie diet and increased physical activity.¹
• Limitations of an open-label study may be related to a bias in the evaluation of the outcomes, efficacy, and/or safety, and analysis was not tested against a placebo-controlled comparison group.
• ⁺Tirzepatide MTD was either 10 mg or 15 mg. Semaglutide MTD was either 1.7 mg or 2.4 mg. Efficacy estimand, mITT population. MMRM analysis.¹
• Efficacy estimand results are supported by the reference, including supplemental information. Data are least-squares mean.¹
  

SAFETY¹

In SURMOUNT-5 trial, the safety profile was consistent with previously reported SURMOUNT trials²

• The most common adverse reactions with tirzepatide were gastrointestinal in nature and were mostly mild to moderate.¹
• Gastrointestinal events primarily occurred during dose escalation and decreased over time.¹

AR= Adverse Reactions

Studied in a randomized, open-label, Phase 3b trial of adults with Obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one Obesity-related complication (e.g., hypertension, dyslipidemia), excluding T2D.^1,2,¶

The study included a 2-week screening period and a 72-week treatment period. Participants in both the tirzepatide and semaglutide treatment arms received lifestyle intervention, including a reduced-calorie diet and increased physical activity¹.

Adverse reaction development and discontinuation rates were not endpoints for this study. Data presented here should not be used to make inferences.

^¶Obesity-related complications" are used as synonymic to "weight-related complications"².

MTD=maximum tolerated dose;

References:
1. Aronne LJ, et al. N Engl J Med. 2025 Jul 3;393(1):26-36. 2. Tirzepatide (Mounjaro) India Prescribing Information | Updated March 2025. 3. Nauck MA et al., Cardiovasc Diabetol. 2022 Sep 1;21(1):169

Therapeutic indication:

Type 2 diabetes mellitus

•as monotherapy when metformin is considered inappropriate due to intolerance or contraindications

•in addition to other medicinal products for the treatment of diabetes.

Weight management

• ≥30 kg/m² (obesity) or

• ≥27 kg/m² to <30 kg/m² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).

For Tirzepatide Prescribing Information, please check: https://image.mc.lilly.com/lib/fe9312747462077971/m/1/0e04e051-5fa2-445b-850d-4f09ef66d35e.pdf

Disclaimer:

This material (including any link) is intended solely for the use of the recipient(s) and may contain confidential information. Any unauthorized review, use, disclosure, copying, or distribution is strictly prohibited. If you are not the intended recipient, please notify the sender immediately and destroy all copies of the material. The information provided in this section is intended solely for the use of registered medical practitioner. This material is being provided to healthcare professionals for their guidance and use. Nothing on this website/microsite/material should be construed as giving medical advice or making recommendations regarding any health-related decision or action.

Mounjaro^®, KwikPen^® and Lilly are registered trademarks of Eli Lilly and Company. To be sold by retail under prescription of Endocrinologist or Internal Medicine Specialists only. For adverse events and safety reporting, please reach out to: mailbox_in-gps@lilly.com For any additional information related to Lilly products, please reach out to: queries_in-medinfo@lilly.com. For further Information about Lilly and Lilly products please contact us at the below address: Atrium Place, 11th Floor, Tower B, Block C, Vanijya Nikunj, Phase V, Udyog Vihar, Sector 19, Gurugram, Haryana 122016, India Ph.: +91-124-4753000/01 | www.lilly.com/in.

CMAT-24323 | 21 August 2026

Eli Lilly and Company. All rights reserved.